Artificial intelligence has been seen as a promising tool for pharmacovigilance (PV) for some time, but only recently has it begun to make a tangible impact. As life sciences organizations face rising case volumes, growing regulatory demands, and pressure to increase efficiency without compromising patient safety, advances in large language models (LLMs), automation platforms, and…